4DMT's 4D-150 Demonstrates Positive 60-Week Results in DME Trial, Reduces Treatment Burden by 78%

4DMT presented positive 60-week results from the 4D-150 SPECTRA clinical trial in diabetic macular edema (DME). 4D-150 demonstrated durable and dose-dependent clinical activity, with sustained gains in visual acuity and anatomic control. The Phase 3 dose (3E10 vg/eye) achieved a 78% reduction in treatment burden compared to projected on-label aflibercept 2mg Q8W. The European Medicines Agency (EMA) has aligned with a proposed single Phase 3 clinical trial for regulatory submission of 4D-150 in DME.